Sanofi to commercialize Vivus ED drug in Africa, Middle East, Turkey and CIS/Russia

12 December 2013

US drugmaker Vivus (Nasdaq: VVUS) has entered into a license and commercialization agreement with French pharma major Sanofi (Euronext: SAN) to commercialize the erectile dysfunction drug avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.

Sanofi will be responsible for obtaining regulatory approval in its territories, and intends to market avanafil under the trade name Spedra or Stendra. Vivus has already entered into an accord with the Sanofi Chemie unit to manufacture and supply the active pharmaceutical ingredient for avanafil, on an exclusive basis in the USA and other territories and on a semi-exclusive basis in the European Union and Latin America (The Pharma Letter August 2).

Vivus to get $61 million in upfront and milestone payments

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK